The THAIBRA Alliance: Harnessing prospective studies to delineate the interplay of immunity and pathogen genetics in Zika and dengue

Grant number: 315770/Z/24/Z

Grant search

Key facts

  • Disease

    Zika virus disease, Congenital infection caused by Zika virus
  • Start & end year

    2025.0
    2030.0
  • Known Financial Commitments (USD)

    $6,536,516.87
  • Funder

    Wellcome Trust
  • Principal Investigator

    Prof. Henrik Salje
  • Research Location

    Thailand, 076
  • Lead Research Institution

    University of Cambridge
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Infants (1 month to 1 year)

  • Vulnerable Population

    Women

  • Occupations of Interest

    Unspecified

Abstract

The factors that drove Zika to cause an explosive pandemic in the Americas, yet generate endemic, often silent transmission in Asia remain unknown. We have a unique opportunity to delineate these factors with community cohorts in Brazil and Thailand, which are situated in high DENV transmission settings, but experienced distinctly different Zika burdens and trajectories. We have developed novel assays to interrogate flavivirus antibody and cell-mediated immunity and pioneered methods to reconstruct infection histories from longitudinal data. We will use these approaches to prospectively determine how the flavivirus immune landscape contributes to Zika and dengue risk. Parallel analyses of a cohort of Brazilian mothers and infants will identify the features of the landscape which influence risk heterogeneity for congenital Zika syndrome (CZS). We will augment these studies with robust genomic surveillance to delineate the interplay between population immunity and the transmission potential for ZIKV. If successful, the proposed studies will directly inform medical countermeasures, provide a generalisable approach to identifying regions of ZIKV circulation and susceptibility to future CZS outbreaks, and prioritise sites for intervention trials. This proposal builds on long-standing partnerships with communities and Ministries of Health, ensuring that the evidence generated will be translated to policy and action.